Article
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002).
Scientific reports - 30 Nov 2021
Yamamoto Gaku, Asahina Hajime, Honjo Osamu, Sumi Toshiyuki, Nakamura Atsushi, Ito Kenichiro, Kikuchi Hajime, Hommura Fumihiro, Honda Ryoichi, Yokoo Keiki, Fujita Yuka, Oizumi Satoshi, Morita Ryo, Ikezawa Yasuyuki, Tanaka Hisashi, Kimura Nozomu, Sasaki Takaaki, Sukoh Noriaki, Takashina Taichi, Harada Toshiyuki, Dosaka-Akita Hirotoshi, Isobe Hiroshi
Abstract excerpt
Osimertinib is a standard of care therapy for previously untreated epidermal growth factor receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding the efficacy and safety of osimertinib as a first-line therapy for elderly patients aged 75 years or older. To assess the potential clinical benefits of osimertinib in this population, this retrospective multi-institutional...
Topics
Join the communities discussing this publication.